1. Home
  2. BFRI vs HIND Comparison

BFRI vs HIND Comparison

Compare BFRI & HIND Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Biofrontera Inc.

BFRI

Biofrontera Inc.

HOLD

Current Price

$1.19

Market Cap

15.0M

Sector

Health Care

ML Signal

HOLD

Logo Vyome Holdings Inc.

HIND

Vyome Holdings Inc.

HOLD

Current Price

$2.17

Market Cap

15.2M

Sector

N/A

ML Signal

HOLD

Company Overview

Basic Information
Metric
BFRI
HIND
Founded
1997
2017
Country
United States
United States
Employees
94
18
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
15.0M
15.2M
IPO Year
N/A
2016

Fundamental Metrics

Financial Performance
Metric
BFRI
HIND
Price
$1.19
$2.17
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
1
1
Target Price
$2.75
$15.00
AVG Volume (30 Days)
393.6K
10.8K
Earning Date
05-13-2026
05-20-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$14.36
N/A
Revenue Next Year
$16.98
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.57
$1.75
52 Week High
$1.27
$12.87

Technical Indicators

Market Signals
Indicator
BFRI
HIND
Relative Strength Index (RSI) 61.55 39.46
Support Level $0.71 $1.78
Resistance Level N/A $2.33
Average True Range (ATR) 0.07 0.09
MACD 0.01 -0.02
Stochastic Oscillator 74.55 0.00

Price Performance

Historical Comparison
BFRI
HIND

About BFRI Biofrontera Inc.

Biofrontera Inc is a United States-based biopharmaceutical company commercializing a portfolio of pharmaceutical products for the treatment of dermatological conditions with a focus on photodynamic therapy. The Company's licensed products, which include Ameluz as well as the BF-RhodoLED and RhodoLED XL lamps (together, the RhodoLED Lamps), are used for the treatment of actinic keratoses (AKs), which are pre-cancerous skin lesions. The company's revenues are derived from within the United States and, therefore, no other geographical segments.

About HIND Vyome Holdings Inc.

Vyome Holdings Inc is a clinical-stage specialty pharmaceutical company working to treat immune-inflammatory and rare diseases of unmet need with next-generation therapeutic solutions. Its product candidates are: VT-1953, a topical gel that is being developed to treat signs and symptoms of malignant fungating wounds in cancer; VT-1908, a repurposed immune modulator to treat steroid-sparing anterior uveitis; and VB1953, which is being developed to treat moderate to severe acne. Vyome has also commercialized two novel reformulated topical anti-fungal products based on the technology platform of Molecular Replacement Therapeutics (MRT) in India: a dandruff lotion and shampoo. It operates in two segments: pharmaceutical products, which generate the maximum revenue, and biotechnology.

Share on Social Networks: